Additive Effects of Retinoic Acid (RA) and Bone Morphogenetic Protein 4 (BMP-4) Apoptosis Signaling in Retinoblastoma Cell Lines

Patrick Müller¹, Rebekka Doliva¹, Maike Busch¹, Claudia Philippeit¹, Harald Stephan², Nicole Dünker¹*

¹ Department of Neuroanatomy, Institute for Anatomy, Medical Faculty, University of Duisburg-Essen, Essen, Germany, ² Division of Haematology and Oncology, Children’s Hospital, University of Duisburg-Essen, Essen, Germany

* nicole.duenker@uk-essen.de

Abstract

Retinoids have been shown to serve promising therapeutic agents for human cancers, e.g. the treatment of neuroblastoma. Synthetic retinoids, specific for particular retinoic acid (RA) receptors, are tested as new therapy strategies. In the present study, application of recombinant retinoic acid (RA) lowers retinoblastoma (RB) cell viability and induces apoptosis in RB cell lines. Combined treatment of RA and bone morphogenetic protein 4 (BMP-4) increases the pro-apoptotic effect of RA in the RB cell lines WERI-Rb1, Y-79, RB355, RBL-30 and RBL-15, indicating an additive effect. We could show that in WERI-Rb1 cells RA/BMP-4 mediated cell death is at least partially caspase-dependent, whereby RA and BMP-4 additively increased (i) Apaf-1 mRNA levels, (ii) caspase-9 cleavage activity and (iii) the number of activated, cleaved caspase-3 positive cells. Compared to single application of RA and BMP-4, combined RA/BMP-4 treatment significantly augments mRNA levels of the retinoic acid receptors (RARs) RARα and RARβ and the retinoic X receptor (RXR) RXRγ suggesting an interaction in the induction of these RA receptor subtypes in WERI-Rb1 cells. Agonist studies revealed that both, RARs and RXRs are involved in RA/BMP-4 mediated apoptosis in WERI-Rb1 retinoblastoma cells. Employing specific RAR subtype antagonists and a RXRβ and RXRγ knockdown, we proved that RA/BMP-4 apoptosis signaling in WERI-Rb1 cells requires the RA receptor subtypes RARα, RARβ, RXRβ and RXRγ. Deciphering signaling mechanisms underlying apoptosis induction of RA and BMP-4 in WERI-Rb1 cells, our study provides useful starting-points for future retinoid-based therapy strategies in retinoblastoma.
Introduction

Retinoids, natural and synthetic vitamin A derivatives, are known to inhibit tumor growth and to suppress carcinogenesis, e.g. in MCF-7 breast cancer and Hep 3B cells [1; 2].

The effects of retinoids are mediated by two classes of nuclear receptors, the retinoic acid receptors (RARs) and the retinoic X receptors (RXRs). RARs are ligand-controlled transcription factors forming heterodimers with RXRs that regulate cell growth, differentiation, survival and death [3; 4]. RARs and RXRs modulate the expression of their target genes by binding to specific retinoic acid response elements (RAREs) [5; 6]. All-trans-RA acid (ATRA) directly activates only RARs. However, in some cells ATRA is converted to 9-cis-RA and this retinoid directly activates RARs and RXRs [7; 8]. Due to their regulatory potential, RARs and RXRs are major drug targets for a variety of pathologies, including cancer. Each subtype of RARs has been implicated in the regulation of cancer development and the anticancer activities of retinoids [9]. RARβ is a tumor suppressor gene [10] and the best characterized RA responsive receptor with a confirmed βRARE binding site. Former studies indicated that up-regulation of the RARβ gene plays a critical role in mediating the apoptosis-inducing effect of retinoids in many different types of cancer cells [11–13]. A large amount of RAR- and RXR-selective ligands, ranging from agonists to antagonists have been designed [14] and are tested as new retinoid-based therapy strategies [3; 15]. Thus, retinoids serve as promising therapeutic agents for many human cancers [9; 16–19].

BMPs are members of the transforming growth factor beta (TGF-β) family, originally identified by their bone-inducing activities. We and others could, however, show that BMPs are also involved in other scenarios besides osteogenesis, e.g. the induction of apoptosis [20]. Former studies demonstrated that BMP-4 and RA synergistically induce apoptosis in P19 embryonal carcinoma cells [21; 22]. If this also holds true for retinoblastoma cells and which molecular mechanisms play a role in a potential synergistic or additive apoptosis induction in RB cells has not been investigated so far.

Against the background to develop novel mechanism-based approaches using retinoids in the prospective treatment of retinoblastoma, in the present study we set out to determine the effects of exogenous RA and combined RA/BMP-4 application on WERI-Rb1 retinoblastoma cell viability and apoptosis and to elucidate signaling mechanism underlying these effects, including the involvement of RARs and RXRs, specific RA receptor subtypes and caspases. Deciphering signaling mechanisms underlying apoptosis induction of RA and BMP-4 in WERI-Rb1 cells, our study provides useful starting-points for future retinoid-based therapy strategies in retinoblastoma.

Materials and Methods

Cell culture

The Rb cell lines RB355 and RB383 (originally established by B. Gallie) and the cell lines RBL-13, RBL-15 and RBL-30, established and first described by Griegel et al. [23] and formerly donated by K. Heise, were kindly provided by Dr. H. Stephan. The human retinoblastoma cell lines Y-79 [24] and WERI-Rb1 [25] originally purchased from the Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures) were kindly provided by Dr. H. Stephan. The cell lines were cultivated as suspension cultures in Dulbecco’s modified Eagle’s medium (DMEM; PAN-Biotech) with 10% fetal calf serum (FCS; PAN-Biotech), 100 U penicillin/ml and 100 µg streptomycin/ml (Invitrogen), 4 mM L-glutamine (Sigma), 50 µM β-mercaptoethanol (Roth) and 10 µg insulin/ml (Sigma) at 37°C, 10% CO2 and 95% humidity. Cells were treated with (i) 1–40 ng/ml of recombinant human BMP-4 (R&D Systems), (ii)
0.005–10 μM of all-trans retinoic acid (ATRA; Sigma; stock: 10 mM in 99.8% ethanol) or (iii) a combination of both for 24 h–48 h. Cells treated with equivalent amounts of HCl/BSA and ethanol vehicle, respectively, were used as controls. For immunocytochemistry, cells were seeded on poly-D-lysine coated (Sigma) coverslips and fixed with 4% paraformaldehyde for 1 h at 4°C.

Cell proliferation and apoptosis detection

In order to determine effects on cell proliferation and apoptosis by 5-bromo-2′-deoxyuridine (BrdU) incorporation, 4',6-diamidino-2-phenylindole (DAPI)-staining and Apo-BrdU TUNEL assay (Life Technologies), 1 x 10⁵ WERI-Rb1 cells, synchronized by serum-starvation, were seeded on cover slips and cultivated in 24-well plates in 300 μl medium containing 5% FCS in the presence of single additives or treated with a combination of several substances as summarized in Table 1. Medium without insulin was used as insulin has been shown to interfere with apoptosis induction (personal observation).

For the determination of effects on cell proliferation, BrdU (5 μM; Sigma) was added 6 h before the end of culture time and BrdU immunocytochemistry was performed as described previously [20]. BrdU positive cells and 4',6-diamidino-2-phenylindole (DAPI)-stained pycnotic nuclei were counted microscopically. For this purpose, at least 10 different fields of view of one coverslip and at least 1000 cells were counted and the number of DAPI-positive, clearly pycnotic cells with condensed nuclei or obvious apoptotic bodies (at least 10) or clearly BrdU-positive stained cells was determined.

WST-1 assay

The WST-1 assay is based on the cleavage of the tetrazolium salt WST-1 to a water soluble formazan by cellular mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases in the sample. For the determination of cell viability, 4 x 10⁴ serum starved WERI-Rb1 cells were seeded in

| Table 1. Application scheme. |
|-----------------------------|
| retinoic acid (RA) | BMP-4 | inhibitor / agonists / antagonists |
| 1 | 5 μM RA | - | - |
| 2 | - | 40 ng/ml BMP-4 | - |
| 3 | 5 μM RA | 40 ng/ml BMP-4 | - |
| 4 | 5 μM RA | - | 38 μM Boc-D-fmk<sup>a</sup> |
| 6 | 5 μM RA | 40 ng/ml BMP-4 | 38 μM Boc-D-fmk |
| 7 | - | - | 5 μM TTNPB<sup>b</sup> |
| 8 | - | 40 ng/ml BMP-4 | 5 μM TTNPB |
| 10 | - | - | 5 μM methoprene acid<sup>c</sup> |
| 11 | - | 40 ng/ml BMP-4 | 5 μM methoprene acid |
| 13 | 5 μM RA | - | 10 μM ER50891<sup>d</sup> |
| 15 | 5 μM RA | 40 ng/ml BMP-4 | 10 μM ER50891 |
| 16 | 5 μM RA | - | 10 μM LE135<sup>e</sup> |
| 18 | 5 μM RA | 40 ng/ml BMP-4 | 10 μM LE135 |

<sup>a</sup>BOC-D-fmk: caspase inhibitor  
<sup>b</sup>TTNPB: RAR agonist  
<sup>c</sup>methoprene acid: RXR agonist  
<sup>d</sup>ER50891: RARα antagonist  
<sup>e</sup>LE135: RARβ antagonist.

doi:10.1371/journal.pone.0131467.t001
96-well plates in 100 μl medium without insulin containing 5% FCS to release cells from growth arrest and various concentrations (0.005, 0.05, 0.5, 5 and 10 μM) RA or respective concentrations of ethanol (controls) were applied. 48 h later, WST-1 reagent was added and the water-soluble formazan dye produced by viable cells was quantified by measuring the absorbance at 440 nm in a microplate reader after 120 min.

**Flow cytometry**

For cell cycle analysis, cells were suspended in 10 mM Tris-hydrochloride (pH 7.5) / 5 mM MgCl₂ / 100 μg/ml propidium iodide and analyzed in a Cytomics FC500 flow cytometer using CXP software (Beckman-Coulter, Germany). The percentage of cells present in the sub-G0/G1 peak, representing apoptotic cells, was calculated after exclusion of cell doublets.

**Inhibition of endogenous caspase activity**

In order to block endogenous caspase activity, Boc-D-fmk (Merck, Germany), a broad spectrum caspase inhibitor was used. WERI-Rb1 cells were seeded on Poly-D-lysine coated coverslips and pre-incubated with 38 μM Boc-D-fmk or DMSO as solvent control for 30 min. Afterwards cells were incubated for 24 h in DMEM without insulin containing 5% FCS supplemented with 5 μM RA and 5 μM RA + 40 ng/ml BMP-4. The number of pycnotic nuclei was assessed by DAPI staining (see above).

**Assay for caspase-9 cleavage activity**

WERI-Rb1 cells were treated for 8 h with 5 μM RA, 40 ng/ml BMP-4 and a combination of both in 300 μl 5% FCS containing medium. The cleavage activity of caspase 9 was analyzed using the Caspase-Glo 9 Assay (Promega) according to the manufacturer’s protocol. Each measurement was performed in triplicate. As a positive control, cells treated for 3 h with 50 μM staurosporine were used.

**Immunocytochemistry**

For immunostaining of active caspase-3 1 x 10⁵ serum starved WERI-Rb1 cells were seeded on cover slips and cultivated in 24-well plates in 300 μl 5% FCS containing medium without insulin in the presence of (i) 5 μM RA, (ii) 40 ng/ml recombinant BMP-4, or (iii) 5 μM RA + 40 ng/ml BMP-4. Cells were fixed with 4% PFA for 1 h, followed by three washes with PBS. Afterwards, cells were fixed with ice-cold 100% methanol for 5 min on ice, washed three times with PBS and incubated for 1 h in blocking solution (0.3% Triton X-100, 4% BSA, 5% normal goat serum (NGS; Dako in PBS). A rabbit monoclonal cleaved caspase-3 antibody (5A1E; Cell Signaling, Danvers MA) was used as a primary antibody and diluted 1:400 in PBS containing 0.1% Triton X100, 4% BSA, and 1% NGS at 4°C overnight. Following three washes with PBS, a species-specific Alexa-594-coupled secondary antibody (Molecular Probes, Life Technologies) was used diluted 1:1,000 in PBS with 1% BSA. Cover slips were embedded in fluorescence mounting medium (Dako) containing DAPI. As controls, in all cases PBS was substituted for the primary antisera in order to test for nonspecific labeling. No specific cellular staining was observed when the primary antiserum was omitted.

**Agonist and antagonist studies**

The following RAR and RXR agonists and antagonists were used: general RAR agonist TTNPB (4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic acid; Sigma-Aldrich) [26]; general RXR agonist methoprene acid (2E,4E-11-Methoxy-3,7,11-trimethyl-2E,
4E-dodecadienoic acid; Enzo Life Sciences) [27; 28]; specific RARα antagonist (ER 50891; Tocris Bioscience) [29] and specific RARβ antagonist (LE 135; Tocris Bioscience) [30].

Retinoids were prepared as 10 mM (agonists) or 2.5 mM (antagonists) stock solutions in DMSO. WERI-Rb1 cells were treated for 48 h with 5 μM TTNPB or methoprene acid and with 10 μM of the RAR antagonists LE135 and ER50891, then fixed with 4% paraformaldehyde for 1 h at 4°C and stained with DAPI. Control cells were treated for 48 h with an equivalent amount of DMSO, the solvent used for the agonists and antagonists.

**Lentiviral expression vectors, production of lentiviral particles and transduction**

For the RXRβ and RXRγ knockdown experiments a “Mission shRNA Plasmid DNA” with a pLKO.1puro backbone was used (Sigma-Aldrich; shRXRβ: clone# TRCN0000021628; shRXRγ: clone# TRCN0000021639). A pPRIME-CMV-Neo-FF3 (p234) vector containing a targeting hairpin sequence against firefly luciferase served as a non-mammalian sh control [31].

For virus production HEK293T cells were transfected with 6 μg of each plasmid DNA: (a) packaging vectors pczVSV-G, pCD NL-BH [32] and (b) the desired expression vector in the presence of 45 μg PEI (Polyethyleneimine, branched, Aldrich). The medium was changed after one day to IMDM with 10% FCS and 1% penicillin/streptomycin and next day viral supernatants were harvested, sterile-filtered (0.45 μM) and cryoconserved.

For the RXRβ and RXRγ knockdown experiments WERI-Rb1 cells were seeded in a 6 well plate (3 x 10⁵ cells/well in 2 ml growth medium as described above). After 24 h the cells were infected with 1 ml shRXRβ or shRXRγ lentiviruses, respectively or with 1 ml lentiviruses expressing a non-silencing shRNA in the presence of polybrene (5 μg/ml, H9268; Sigma), serving as a control. After 24 h, additional 2 ml of normal growth medium was added to the cells, and after another 48 h the medium was completely changed. RNA was isolated and DAPI stains were performed six days after transduction. The experiments were performed in duplicates.

**RNA isolation and Quantitative Real-time PCR**

RNA isolations from the RB cell lines were performed using the NucleoSpin RNA II kit (Machery and Nagel), and cDNA was synthesized with the QuantiTect Reverse Transcription Kit (Qiagen) following the manufacturer’s protocols. Pooled human adult total retinal RNA, used as a reference, was purchased from Clontech (cat.# 636579). Quantitative Real-time PCR analyses were performed using a 7300 Real-Time PCR System (Applied Biosystems). The following Taqman Gene Expression Assays (Applied Biosystems) were used: RARα: Hs00940446_m1; RARβ: Hs00977140_m1; RARγ: Hs00199455_m1; RXRγ: Hs00199455_m1; and Apaf-1: Hs00559421_m1. GAPDH (ID Hs99999905_m1) as an endogenous control. Real-time PCR reactions were performed in duplicate with a total volume of 20 μl applied to the following program: 2 min 50°C, 10 min 95°C, followed by 40 cycles of 15 sec 95°C and 60 sec 60°C. Relative quantification was calculated by the 7300 Real-Time PCR System software (Applied Biosystems). Results represent mean values of at least four independent experiments.

**Statistical analysis**

All assays were performed in triplicate. Data represent means ± SEM of at least three independent RNA preparations from independent RB cell cultures. Results were analysed by a Student’s t-test or one way Annova and Newman-Keuls Post test. Values were considered significantly different if *P<0.05, **P<0.01 or ***P<0.001.
Results

RA lowers cell viability and induces apoptosis in WERI-Rb1 cells

We set out to determine the effect of increasing concentrations of exogenously applied RA on RB cell viability. In WST-1 assays, 0.5 μM and 5 μM RA significantly lowered WERI-Rb1 cell viability to values between 84% and 87%, whereby higher concentrations of RA (10μM) were not able to further increase this effect (Fig 1A). In order to determine if this significant decrease in cell viability is due to a decrease in cell proliferation or rather an increase in apoptosis, we counted the number of BrdU-stained cells (Fig 1B) and DAPI-positive, apoptotic nuclei (Fig 1C), respectively. Application of increasing amounts of RA had no significant effect on the number of BrdU-positive, proliferating cells (Fig 1B), but significantly induced apoptosis in WERI-Rb1 cells (Fig 1C). As the application of 0.05 μM RA did not exert a significant effect in our WST-1 assays, this concentration was not included in the BrdU and DAPI cell count approaches.

RA and BMP-4 additively induce apoptosis in retinoblastoma cell lines

In the present study, the effect of RA on cell survival and apoptosis in WERI Rb1 cells was only moderate and the effect of BMP-4, determined in a former study by our group [20], though significant, was likewise low. In this context, other groups showed that a combination of BMP-4 and RA significantly increased apoptosis in cells, in which application of RA and BMP-4 alone only exerted small apoptotic effects [21; 22] and that this synergistic apoptosis induction is dose-dependent.

We thus set out to investigate a possible synergistic or additive effect of combined RA and BMP-4 application in the induction of apoptosis in WERI-Rb1 cells and to reveal a potential concentration dependence of this effect. For this purpose, we added increasing amounts of BMP-4 to WERI-Rb1 cells treated with 0.5 μM (Fig 2A) or 5 μM RA (Fig 2B). While the addition of low concentrations of BMP-4 (1 ng/ml) resulted in no increase in the amount of subG0/G1 DNA, the addition of 10 ng/ml BMP-4 resulted in a significant increase in the amount of dead cells compared to RA single treatment (Fig 2A and 2B).

In a second set of experiments, we titrated the RA concentration in the presence of 10 ng/ml and 40 ng/ml BMP-4. As shown in Fig 2C and 2D, there is also a dose-dependent response to RA in that the addition of higher concentrations of RA (5 μM and 10 μM) resulted in a higher proportion of fragmented DNA, whereas low concentrations of RA (0.05 μM and 0.5 μM) did not increase the number of cells in the sub G0/G1 fraction. Thus, combined application of RA and BMP-4 results in a dose-dependent increase of the pro-apoptotic effect obtained by single factor treatment, indicating an additive interaction of both factors in apoptosis induction in WERI-Rb1 cells.

BrdU cell counts indicated that RA/BMP-4 double treatment had no significant impact on WERI-Rb1 cell proliferation (S1 Fig).

In long-time experiments (S2 Fig), we detected slightly higher apoptosis levels 48 h after application of RA, BMP-4 or a combination of both, but only in double treatment approaches and only after re-stimulation (Figs. A and B in S2 Fig). Seventy-two hour treatment resulted in an increase in the number of apoptotic cells in single treatment approaches, whereas re-stimulation after 24 h and 48 h slightly augmented the pro-apoptotic effect of combined factor treatment (Figs. C and D in S2 Fig).

We performed additional Apo-BrdU TUNEL assays in order to validate our DAPI cell count data. Exemplary counts of TUNEL-positive WERI-Rb1 cells seeded on coverslips and
Fig 1. Effect of RA treatment on cell viability, cell proliferation and cell death in the retinoblastoma cell line WERI-Rb1. Cells were grown in medium containing indicated concentrations of RA or ethanol (control; set as 100%). Application of RA decreased the viability of WERI-Rb1 cells as determined by WST-1 assays (A). Cell counts from BrdU incorporation experiments (B) and counts of DAPI-positive, pyknotic nuclei (C) were performed to determine proliferation and apoptosis rates, respectively. Application of increasing
counterstained with Propidium iodide, revealed apoptosis rates mirroring and thereby confirming our data from DAPI cell counts after RA, BMP-4 and combined treatment (S3 Fig).

DAPI cell counts in the four additional RB cell lines Y-79, RB355, RBL-30 and RBL-15 confirmed the data gained in WERI-Rb1 cells, generalizing the notion of a pro-apoptotic effect of RA, BMP-4 and combined treatment in RB cell lines (S4 Fig). Interestingly, in RBL-15 cells (Fig D in S4 Fig), derived from a bilateral tumor, apoptosis induction by combined RA/BMP-4 treatment was considerably higher compared to the effects observed in Y-79 (Fig A in S4 Fig), RB355 (Fig B in S4 Fig) and RBL-30 (Fig C in S4 Fig), established from unilateral retinoblastomas, more or less mirroring the pro-apoptotic effects obtained in WERI-Rb1 cells.

Fig 2. FACS analyses of WERI-Rb1 cells. WERI-Rb1 cells were treated for 48 h with two fix concentrations of RA (0.5 μM and 5 μM; A,B) or BMP-4 (10 ng/ml and 40 ng/ml; C,D) and rising concentrations of BMP-4 (1–40 ng/ml) or RA (0.05–10 μM), respectively. Under these conditions, RA and BMP-4 additively and dose-dependently induced an increase in subG0/G1, representing apoptotic cells. Gray bars: untreated control cells; white bars: cells treated (+) or not (−) with equivalent concentrations of HCl/BSA, the solvent for BMP-4, ethanol, the solvent for RA, or both. Values are means from 3–4 independent assays ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 statistical differences calculated by one way Annova and Newman-Keuls Post test.
Caspases are involved in RA and RA/BMP-4 induced apoptosis in WERI-Rb1

Previous studies by our group demonstrated that BMP-4 induced apoptosis in WERI-Rb1 cells is at least partially caspase-dependent [20]. In the present study, we further investigated the involvement of caspases in RA and RA/BMP-4 induced apoptosis in this retinoblastoma cell line using Boc-D-fmk, a broad spectrum caspase inhibitor. WERI-Rb1 cells were pre-incubated with Boc-D-fmk or DMSO, its solvent and pre-treated cells were incubated for 24 h in DMEM containing no insulin and only 5% FCS supplemented with 5 μM RA and 5 μM RA + 40 ng/ml BMP-4 (Fig 3A). By these experiments, we confirmed that in WERI-Rb1 cells endogenous apoptosis is caspase independent since the number of pycnotic nuclei was not significantly reduced in Boc-D-fmk treated cells compared to untreated controls (Fig 3A). DMSO, the solvent for Boc-D-fmk did not induce any significant changes in the number of DAPI-positive, pycnotic nuclei compared to untreated control cells in the concentration used (data not shown). Our data indicate that RA as well as RA/BMP-4 mediated cell death is at least partially caspase-dependent, as the number of pycnotic nuclei is significantly lower after BOC-D-fmk pre-treatment (Fig 3A).

As BMP-4 [20], RA, and RA/BMP-4 mediated apoptosis in WERI-Rb1 cells is at least partially caspase-dependent, we examined whether caspase-3 is activated by the respective treatments (Fig 3C and 3D). Immunocytochemical staining with a specific cleaved caspase-3 antibody (red immunofluorescence in Fig 3D and 3G) and counterstaining with DAPI (blue fluorescence in Fig 3C and 3F) revealed that WERI-Rb1 cells treated for 24 h with a combination of RA and BMP-4 displayed significant higher numbers of cleaved, activated caspase-3-positive cells (Fig 3H) compared to untreated control cells (Fig 3E). Quantification of cleaved caspase-3 positive cells (Fig 3B) proved that compared to RA and BMP-4 single treatment, RA/BMP-4 double treatment further increased the level of activated caspase-3 cells (Fig 3B), strongly suggesting that during apoptosis induction in WERI-Rb1 cells, RA and BMP-4 additively induce cleavage and thereby activation of caspase-3.

Cleavage activity of caspase-9—being upstream of caspase-3—significantly increased 8 h following administration of 5 μM RA or 40 ng/ml BMP-4 alone, and was further significantly increased by RA/BMP-4 double treatment (Fig 3I), strongly arguing for an additive enhancement of caspase-9 cleavage activity during RA/BMP-4 mediated apoptosis induction in WERI-Rb1 cells.

Apaf-1 is induced by RA/BMP-4 double treatment

Apaf-1 (apoptotic protease activating factor 1) molecules assemble into a key cell death platform known as the apoptosome that mediates the activation of pro-caspase-9, leading to activation of caspase-3 and apoptosis [33]. We thus set out to investigate if this key player in apoptosis signaling is regulated by RA, BMP-4 or additively by both factors. Our Real-time data revealed that Apaf-1 mRNA levels remain unchanged upon treatment with 5 μM RA and 40 ng/ml BMP-4, whereas Apaf-1 transcript levels significantly increased 48 h upon double treatment (Fig 3J), indicating an additive interaction also at this signaling level.

RA and BMP-4 signaling up-regulates the expression of specific RAR and RXR subtypes

A ligand like RA can only mediate its effects when its receptors are expressed in the respective cell. Altered RA receptor levels determine the induction of apoptosis and are known to be associated with different cancers [34–36; 11]. Thus, in the study presented, we set out to determine...
Fig 3. Involvement of caspases in RA and BMP-4 mediated apoptosis induction in WERI-Rb1 cells. A, Blockage experiments with a broad spectrum caspase inhibitor (Boc-D-fmk) in the presence (+) or absence (-) of RA and BMP-4. B, Quantification of cleaved (= activated) caspase-3 positive cells after treatment with RA, BMP-4 or both factors. C-H, Immunocytochemical caspase-3 staining. I, Up-regulation of caspase-9 cleavage activity following administration of RA, BMP-4 or a combination of both. Untreated cells, revealing the endogenous caspase-9 cleavage activity, served as a standard and were set as 1. Cells treated with the solvent for RA and BMP-4 (see material and method), respectively, served as controls (ctr.). J, Induction of Apaf-1 upon application of RA, BMP-4 and RA+BMP-4 as revealed by Real-time PCR. Messenger RNA expression levels at the beginning of the treatment (0h) were used as a reference and set as 1. Values are means from 3 independent experiments ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 statistical differences calculated by Student’s t-test (A) or statistical differences calculated by one way Annova and Newman-Keuls Post test (B,I,J).

doi:10.1371/journal.pone.0131467.g003
if RB cell lines express all receptor subtypes essential for RA signaling. Analyzing RARα, β, γ and RXRα, β, γ subtype expression, we observed that all RB cell lines analyzed (RBL-13, RBL-15, RBL-30, RB355, RB383, WERI-Rb1, Y-79) constitutively express transcripts for all RAR and RXR receptor subtypes (S5 Fig).

Due to their regulatory potential, RARs and RXRs are major drug targets for cancer therapies. Thus, we next set out to investigate the effects of RA, BMP-4 and RA/BMP-4 double treatment on RAR and RXR subtype expression. As revealed by Real-time PCR, RARα levels significantly increased upon administration of RA (Fig 4A). Treatment of WERI-Rb1 cells with 40 ng/ml BMP-4, shown to be the optimal concentration to induce effects in this cell line [20], likewise significantly up-regulated RARα levels after 24 h and 48 h (Fig 4A), and RA/BMP-4 double treatment further augmented RARα mRNA expression, suggesting an additive interaction in which the factors boost each other’s effect.

RARβ is significantly up-regulated 24 h after exogenous application of RA (Fig 4B). Co-application of BMP-4, which had no significant effect when applied alone, significantly increased this effect in RA/BMP-4 double treatment settings. Forty-eight hours after single application of RA or BMP-4 no significant effect on RARβ expression was detectable, whereas RARβ mRNA levels were more than doubled by RA/BMP-4 double treatment, strongly indicating an synergistic interaction of RA and BMP-4 in RARβ induction.

RARγ is significantly up-regulated 24 h upon RA administration, but this modulatory effect could not be enhanced by additional application of BMP-4, which likewise had no influence on RARγ levels when applied alone (Fig 4C). Thus, the up-regulation seen upon RA/BMP-4 double treatment is solely attributable to RA.

It turned out that RXRα is not inducible neither by application of RA or BMP-4 alone, nor by RA/BMP-4 double treatment (Fig A in S6 Fig).

RXRβ is significantly up-regulated by BMP-4, whereas its level remained unchanged upon application of RA (Fig B in S6 Fig). BMP-4’s effect could not be increased by additional application of RA in double treatment experiments (Fig B in S6 Fig), indicating that RXRβ is solely regulated by BMP-4.

RXRγ mRNA levels significantly increased 24 h upon administration of RA and BMP-4 (Fig 4D). RA/BMP-4 double treatment further enhanced RA’s and BMP-4’s effect significantly, indicating that RXRγ expression is additively regulated by both agents.

We used the housekeeping gene GAPDH as an endogenous control in our RT- and Real-time PCR analyses. In order to verify that RA/BMP-4 treatment does not significantly modify the levels of GAPDH in WERI-Rb1 cells, we performed Real-time PCR analyses with additional housekeeping genes. Our data confirm that the additive induction of RA receptor mRNAs by RA/BMP-4 treatment—exemplified for the induction RARα, RARβ and RARγ after 24 h—persists normalizing transcript levels against 18S rRNA or actin expression (S7 Fig).

**Apoptosis induction by RA and BMP-4 depends on the activation of RARs and RXRs**

ATRA can directly activate only RARs; however, in some cells ATRA is converted to 9-cis-RA [37] and this retinoid can directly activate RARs and RXRs [7; 8]. Since apoptosis in e.g. HL-60 cells requires both, RAR and RXR activation [38], we set out to determine the role of each receptor class in RA and RA/BMP-4 mediated apoptosis induction of WERI-Rb1 cells. It is unknown whether metabolism of ATRA to 9-cis-RA might provide an RXR signal in WERI-Rb1 cells and we therefore used TTNPB, a stable RAR agonist and methoprene acid, a RXR agonist to assess the requirement for RAR and RXR activation during RA- and RA/BMP-4 induced apoptosis (Fig 5). TTNPB alone and in combination with BMP-4 clearly induced
apoptosis 48 h after application, but the level of DAPI-positive, pycnotic nuclei were significantly lower compared to RA and RA/BMP-4 treated cells, indicating that RA and RA/BMP-4 induced apoptosis in WERI-Rb1 cells is mediated by RARs, but concomitant activation of RXRs is required to trigger the full pro-apoptotic effect (Fig 5A). Methoprene acid likewise induced apoptosis alone and in combination with BMP-4, but again, cell death levels did not reach those found after RA and RA/BMP-4 treatment, indicating that besides the induction of RXRs, activation of RARs is equally essential for RA and RA/BMP-4-mediated apoptosis.

**Fig 4.** Induction of RAR and RXR subtypes by RA, BMP-4 and RA/BMP-4 double treatment in WERI-Rb1 cells as revealed by Real-time PCR. Messenger RNA expression levels at the beginning of the treatment (0h) were used as a reference and set as 1. The housekeeping gene GAPDH was used as an endogenous control. Data confirm an additive induction of RARα (A), RARβ (B) and RXRγ (D) by RA/BMP-4 double treatment, whereas the up-regulation of RXRγ (C) is solely attributable to RA. Values are means from four to five independent assays ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 statistical differences calculated by one way Annova and Newman-Keuls Post test.

doi:10.1371/journal.pone.0131467.g004
induction in WERI-Rb1 cells (Fig 5B). Thus, our data argue for a requirement of both RAR subtypes in RA and RA/BMP-4 apoptosis induction in WERI-Rb1 cells.

**RA and RA/BMP-4 apoptosis signaling in WERI-Rb1 cells involves RARα, RARβ, RXRβ and RXRγ**

Each subtype of RARs has been implicated in the regulation of cancer development. Despite these studies, further investigation is needed to dissect the relevance of each receptor subtype in cancer cells in general and in retinoblastoma in particular. Compounds that possess specific binding properties, that is, receptor-selective retinoid antagonists, are useful tools for the precise elucidation of the mechanisms of RA actions. Using ER50891, a specific RARα antagonist [29] and LE 135, a selectively RARβ antagonist [30], in the study presented, we could clearly demonstrate that apoptosis induction by RA/BMP-4 signaling in WERI-Rb1 cells requires both RAR subtypes, RARα and RARβ (Fig 6A). Application of RA or RA/BMP-4 together with 10 μM ER50891 or 10 μM LE135 for 24 h significantly lowered the number of DAPI-positive, pycnotic nuclei compared to cells cultured in the absence of RAR antagonist. Higher concentrations (50 μM; S8 Fig) of ER50891 did not increase this effect (Fig A in S8 Fig); higher concentrations (50 μM) of LE135 likewise did not further reduce apoptosis levels (Fig B in S8 Fig).

Combination of both RAR subtype antagonists and application together with RA or RA/BMP-4 did not result in a further decrease in apoptotic cell levels, suggesting that one or more additional RA receptors are involved.

It has been shown that RARs form heterodimers with RXRs, but our data indicated that RXRα is not inducible by RA or BMP-4 and RXRβ seems to be exclusively regulated by BMP-4. Thus, RXRγ, additively induced by RA/BMP-4 treatment, was the most promising candidate to form heterodimers with RARα and RARβ, shown to be involved in RA/BMP-4 apoptosis signaling.

As no subtype specific RXRβ and RXRγ antagonists are commercially available, we designed an RXRβ and an RXRγ knockdown (KD). Lentiviral transduction of WERI-Rb1 cells with shRXRβ and shRXRγ lentiviral particles (S9 Fig) reduced the expression of RXRβ by 78% (Fig A in S9 Fig) and RXRγ by 93% (Fig B in S9 Fig). Our functional study, in which we treated cells with RA or RA + BMP-4 in the presence or absence of both, RARα and RARβ antagonists revealed that in WERI-Rb1 cells with a RXRγ KD apoptosis was less significantly induced compared to cells expressing the RXRγ gene (Fig 6B). Compared to untreated controls, RA was not able to induce apoptosis in WERI-Rb1-RXRγ KD cells treated with both RARα and RARβ antagonists, strongly arguing for an important role of all three receptor subtypes in RA-mediated apoptosis induction.

The combination of RXRγ KD with an application of RARα and RARβ antagonists significantly decreased the number of apoptotic cells compared to antagonist treatment alone, but was not sufficient to completely abolish apoptosis induction by RA and BMP-4, suggesting that an additional receptor—RXRβ or /and a BMP receptor—is required to mediate the additive apoptosis effects of a combined RA/BMP-4 treatment.

As RXRβ expression is induced by BMP-4 (Fig B in S6 Fig), the additive effect in response to a combined RA/BMP-4 treatment might not only be dependent on RARα, RARβ and RXRγ but also on RXRβ. We thus designed an RXRβ single and an RXRβ/RXRγ double KD to address the question if the RXRβ subtype receptor might also be crucial for a combined treatment induced apoptosis.

In WERI-Rb1 cells with an RXRβ single KD, treatment with RA + BMP-4 induced significantly less apoptosis compared to control cells expressing the RXRβ gene (Fig 7). In RXRβ/RXRγ double KD cells, combined RA/BMP-4 treatment in the presence of RARα and RARβ antagonists still slightly, but compared to control cells no longer significantly induces
Fig 5. RAR and RXR agonist studies. Using 5 μM TTNPB, a stable RAR agonist (A) and 5 μM methoprene acid, a RXR agonist (B) in the presence (+) or absence (-) of RA and BMP-4 revealed the involvement of both RA receptor subtypes in RA and RA/BMP-4 mediated apoptosis induction in WERI-Rb1 cells. Values are means from two to three independent experiments ± SEM. **P < 0.01; ***P < 0.001 statistical differences calculated by one way ANOVA and Newman-Keuls Post test.

doi:10.1371/journal.pone.0131467.g005
Fig 6. RARα and RARβ antagonist (A) and RXRγ knockdown (B) studies. A. Application (+) of ER50891, a specific RARα antagonist or LE 135, a selectively RARβ antagonist for 24 h disclosed the involvement of both RAR subtypes in RA/BMP-4 mediated apoptosis induction in WERI-Rb1 cells. B. WERI-Rb1 cells with a RXRγ knockdown (sh RXRγ) and non-silencing controls were treated for 24 h with RA or a combination of RA and BMP-4.
and BMP-4 in the presence (+) or absence (-) of a RARα antagonist (ER 50891) and a RARß antagonist (LE 135). Values are means from 3 independent assays ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 statistical differences calculated by one way Annova and Newman-Keuls Post test.

doi:10.1371/journal.pone.0131467.g006

apoptosis, strongly arguing for the additional involvement of the RXRß receptor subtype in RA/BMP-4-mediated apoptosis induction.

**Discussion**

Retinoids are already used in the treatment of epithelial cancer and promyelocytic leukemia [19; 39–42] and discussed for the therapy and / or chemoprevention of breast and gastric cancer [35; 43] as well as neuroblastoma [39]. The mechanisms of RA in cancer treatment include inhibition of cell proliferation, promotion of terminal tumor cell differentiation and induction of apoptosis [9]. It has been shown that RA has profound effects on cell growth and cause apoptosis in diverse tumor cells [1; 2; 44]. In the present study, RA clearly lowered the viability of WERI-Rb1 retinoblastoma cells and significantly increased the number of pycnotic nuclei, but...
had no detectable effect on the number of proliferating cells and no changes in the cell cycle profile could be detected. Our data are in full accordance with other studies likewise reporting that RA did not affect cell cycle distribution but triggered pronounced apoptosis in MCF-7 cells [45].

Former studies by our lab already demonstrated that BMP-4 induces apoptosis in WERI-Rb1 cells [20]. Though significant, BMP-4’s pro-apoptotic effect was low. In the present study, RA alone likewise only exerted small effects on apoptosis. Glozak and Rogers [21] likewise reported that RA alone induced apoptosis in only 10–15% of the cells and BMP-4 alone only minimally induced apoptosis, whereas the combination of RA and BMP-4 synergistically induced apoptosis in 40% of the P19EC cell population. Our results from experiments, in which we titrated RA against a fixed BMP-4 concentration and vice versa are in accordance with these findings, demonstrating that combined application of RA and BMP-4 results in increased cell death levels compared to single factor treatment. We likewise observed a significant, however, additive interaction of RA and BMP4 in the induction of apoptosis in different retinoblastoma cell lines. The reason for the distinct responses of RB and P19EC cells to RA, BMP-4 and combined treatment can be explained by the fact that cell lines with a completely different genetic, species and tissue-specific background were analyzed: on the one hand RB cells derived from primary human retinoblastomas with mutations or a complete loss of the Rb1 gene and on the other hand embryonic carcinoma cells derived from a murine teratocarcinoma.

Caspases, a family of cysteine proteases, are major executioners of apoptosis. Poulaki et al. [46] showed that the RB cells lines Y-79 and WERI-Rb1 do not express caspase-8. A former study by our group, however, demonstrated that BMP-4 mediated apoptosis in WERI-Rb1 cells is at least partially caspase-dependent [20]. It has been reported that RA- and RA/BMP-4 induced apoptosis in different tumor cells is related with an up-regulation and / or activation of caspase-3 [18; 22; 47]. In the study presented here, caspase blockage experiments and immunocytochemical stains revealed that RA and RA/BMP-4 induced apoptosis in WERI-Rb1 cells likewise involves cleavage and activation of caspase-3. In contrast to former findings [45], we did not detect an increase in full caspase-9 transcript levels upon administration of RA, BMP-4 or RA/BMP-4 double treatment (S10 Fig), however, observed a highly significant increase in caspase-9 cleavage activity following RA and BMP-4 administration, which was further increased by RA/BMP-4 double treatment. Our results are in accordance with former findings demonstrating that in P19 embryonal carcinoma cells, RA and BMP-4 induce the activation of caspase-9, being upstream of caspase-3 in the RA/BMP-4 mediated apoptosis enzyme cascade [22].

Apaf-1 is a cytoplasmic protein that forms one of the central hubs in the apoptosis regulatory network. Apaf-1 forms an oligomeric apoptosome that binds and cleaves caspase-9 [48]. Administration of RA had no effect on Apaf1 mRNA expression in mammary carcinoma cells [45]. In our study, Apaf-1 transcript levels likewise remained nearly unchanged upon application of RA, however, showed a significant up-regulation upon BMP-4 treatment. Co-application of RA in RA/BMP-4 double treatment approaches further increased Apaf-1 mRNA levels, clearly indicating to an additive interaction of both factors in Apaf-1 induction in WERI-Rb1 cells and indirectly confirming the involvement of caspases.

Previous studies found different receptor subtypes to be essential for apoptosis induction, depending on the carcinoma cell types. In P19 embryonal carcinoma cells RA/BMP-4 induced apoptosis is mediated through the activation of RARs and not RXRs [21]. Nagy et al. [38], by contrast, demonstrated that ligand activation of RXRs is essential for the induction of RA-mediated apoptosis in the leukemic myeloid precursor cell line HL-60 [38]. In the study presented, agonist studies revealed that both RARs and RXRs are involved in RA/BMP-4’s
apoptosis induction in WERI-Rb1 retinoblastoma cells. Besides, we demonstrated that RA/BMP-4 apoptosis signalling in WERI-Rb1 cells requires the RA receptor subtypes RARα, RARβ and RXRγ. Our results are in good accordance with data from Glozak and Rogers [21] showing that in P19 embryonal carcinoma cells RA/BMP-4 induced apoptosis is mediated through the specific activation of RARα [21]. The authors, however, found RARγ also to play a role [21], whereas in WERI-Rb1 cells RXRγ is up-regulated by RA, but we could not augment this effect by co-application of BMP-4. The up-regulation of RARβ is in good accordance with other studies showing that the level of RARβ transcript increases dramatically in different cell types and tissues in response to RA [49; 50]. Using gene microarray chips, Li et al. [51] described the effects of RA on global gene expression patterns in WERI-Rb1 cells. The authors showed that treatment of WERI-Rb1 cells with ATRA for 48 h led to a significant up-regulation of RXRγ mRNAs. However, no changes in the expression level of the different RAR subtypes were detected by the microarray assay opposing data from our study, reporting on an up-regulation of RARα, RARβ and RARγ levels. The reason for these different findings is most likely the different duration of the ATRA treatment. Li et al. treated Weri-Rb-1 cells for 3h, 48 h and 7 days, while we chose a 24 h and 48 h treatment. In our setting the up-regulation of RARβ and RARγ mRNA levels by ATRA after 24 h is transient and no longer visible after 48 h. After 3h, the earliest time point of the study by Li et al. [51] the receptors are probably not yet induced and an up-regulation of RARα after 48 h not be high enough to induce a significant change in hybridization intensities in chip analyses.

In the present study, combined antagonist and knockdown approaches revealed that RA induced apoptosis is mediated through RARα, RARβ, RXRβ and RXRγ receptors. Though statistically not significant, combined application of RA/BMP-4 in RXRβ/RXRγ double KD cells additionally treated with RARα and RARβ antagonists, still slightly induces apoptosis. Thus, an additional receptor might be involved in mediating the additive effects of RA and BMP-4. As application of RA significantly up-regulated the mRNA level of BMPR II (S11 Fig), we hypothesize that this BMP receptor subtype might also contribute to RA/BMP-4 mediated cell death induction in WERI-Rb1 cells. Fujita et al. [22] likewise hypothesized that in P19 embryonic carcinoma cells up-regulation of BMPRII upon RA treatment makes the cells competent to respond to BMP-4 signals thus, inducing the synergistic effect of RA and BMP-4.

Summarizing, the present study demonstrates that a combined application of RA and BMP-4 amplifies the effect of single factor treatment and the signaling molecules involved, especially the receptors induced, might serve useful starting-points for future therapeutic approaches in retinoblastoma therapy, e.g. in combination with conventional chemotherapy. Retinoids are already used for the treatment of a number of diseases and new synthetic retinoids, specific for particular RA receptors may in the future be used for the treatment of other disorders including retinoblastoma. Ongoing studies will reveal further details on the signaling pathway underlying RA/BMP-4 mediated apoptosis induction in retinoblastoma cells and the effects of a combination with chemotherapeutic agents.

**Supporting Information**

**S1 Fig.** Effect of RA, BMP-4 and combined RA/BMP-4 treatment on cell proliferation in the retinoblastoma cell line WERI-Rb1 as determined by BrdU cell counts. n.s.: no significant statistical difference. (TIF)

**S2 Fig.** Apoptosis induction by RA, BMP-4 and combined treatment in WERI-Rb1 cells after long-time treatment. Cell counts of DAPI-positive, pycnotic nuclei were performed to determine apoptosis rates 48 h (Fig A,B) and 72 h (Fig C,D) after treatment with RA, BMP-4
or a combination of both, with (Fig B,D) and without (w/o; Fig A,C) restimulation after 24 h and 48 h. Forty-eight hours after application of RA, BMP-4 or a combination of both (Fig A,B), we detected higher apoptosis levels compared to those observed upon 24 h stimulation, but only in double treatment approaches and only after re-stimulation. Longer treatment (72h; Fig C,D) resulted in an increase in the number of apoptotic cells in single treatment approaches, whereas re-stimulation after 24 h and 48 h augmented the pro-apoptotic effect of combined factor treatment. **P < 0.01; ***P < 0.001 significant statistical differences compared to the control group calculated by one way Annova and Newman-Keuls Post test comparing all experimental groups.

**S3 Fig.** Apoptosis induction by RA, BMP-4 and combined treatment in WERI-Rb1 cells as detected by Apo-BrdU TUNEL assay. 72 h after single stimulation with RA, BMP-4 or a combination of both, TUNEL-positive cells were counted manually and apoptosis rates were calculated as the percentage of total, Propidium iodide counterstained cells. **P < 0.01; ***P < 0.001 significant statistical differences calculated by one way Annova and Newman-Keuls Post test.

(TIF)

**S4 Fig.** Apoptosis induction by RA, BMP-4 and combined treatment in Y-79 (Fig A), RB355 (Fig B), RBL-30 (Fig C) and RBL-15 (Fig D) cells. Cell counts of DAPI-positive, pyknotic nuclei were performed to determine apoptosis rates after treatment with RA, BMP-4 or a combination of both. 72 h treatment without restimulation resulted in a significant increase in the number of apoptotic cells in single as well as in double treatment approaches. *P < 0.05, **P < 0.01; ***P < 0.001 significant statistical differences calculated by one way Annova and Newman-Keuls Post test.

(TIF)

**S5 Fig.** RARα, β, γ and RXRα, β, γ subtype expression in different RB cell lines. A healthy human retina pool served as a reference and was set as 1.

(TIF)

**S6 Fig.** RXRa (Fig A) and RXRβ (Fig B) transcript levels after RA, BMP-4 and RA/BMP-4 double treatment as revealed by RT-PCR. Cells treated with the solvents for RA and BMP-4 (see material and methods) served as controls (ctr.). *P < 0.05 statistical differences compared to the control group calculated by Student’s t-test.

(TIF)

**S7 Fig.** Relative RAR subtypes transcript levels in WERI-Rb1 cells after RA, BMP-4 and RA/BMP-4 double treatment normalized against 18S rRNA (Fig A,C,E) and actin (Fig B,D, F). Compared to Real-time PCR analyses in which the housekeeping gene GAPDH was used as an internal control, the additive induction of RA receptor mRNA by RA/BMP-4 double treatment—exemplified for the induction RARα, RARβ and RARγ after 24 h—persisted normalizing transcript levels against 18S rRNA or actin expression. Messenger RNA expression levels at the beginning of the treatment (0h) were used as a reference and set as 1.

(TIF)

**S8 Fig.** RARα and RARβ antagonist studies. Black bars: treatment with 10 μM ER50891 (RARα antagonist; Fig A) or LE135 (RARβ antagonist; Fig B); grey bars: treatment with 50 μM of the respective antagonists. *P < 0.05; ***P < 0.001 statistical differences compared to the control group calculated by Student’s t-test. n.s.: no significant statistical difference.

(TIF)
S9 Fig. RXRβ and RXRγ transcript and protein levels after shRNA-mediated knockdown. Expression of RXRβ and RXRγ mRNA and RXRγ protein levels after shRNA-mediated knockdown as revealed by Real-time-PCR (Fig A,B), RT-PCR (inset in Fig A) and Western Blot (Fig C).

(TIF)

S10 Fig. Caspase-9 transcript levels upon administration of RA, BMP-4 and RA/BMP-4 double treatment. Cells treated with the solvents for RA and BMP-4 (see material and methods) served as controls (ctr.). n.s.: no significant statistical difference.

(TIF)

S11 Fig. BMPR II expression levels upon RA, BMP-4 and RA/BMP-4 double treatment. Cells treated with the solvents for RA and BMP-4 (see material and methods) served as controls (ctr.). **P < 0.001 statistical difference compared to the control group calculated by Student’s t-test. n.s.: no significant statistical difference.

(TIF)

Acknowledgments
The authors would like to thank S. Rotthus, U. Gerster and U. Laub for excellent technical assistance and D. Gioè for proofreading of the manuscript.

Author Contributions
Conceived and designed the experiments: ND MB. Performed the experiments: PM RD CP. Analyzed the data: PM RD MB CP ND. Contributed reagents/materials/analysis tools: HS. Wrote the paper: ND PM RD MB HS.

References
1. Mangiarotti R, Danova M, Alberici R, Pellicciari C. All-trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. Br J Cancer 1998; 77(2): 186–91. PMID: 9460987
2. Kim DG, Jo BH, You KR, Ahn DS. Apoptosis induced by retinoic acid in Hep 3B cells in vitro. Cancer Lett. 1996; 107(1): 149–59. PMID: 8913280
3. Le Maire A, Bourguet W. Retinoic Acid receptors: structural basis for coregulator interaction and exchange. Subcell Biochem. 2014; 70: 37–54. doi: 10.1007/978-94-017-9050-5_3 PMID: 24962880
4. Piskunov A, Al Tanoury Z, Rochette-Egly C. Nuclear and extra-nuclear effects of retinoid Acid receptors: how they are interconnected. Subcell Biochem. 2014; 70: 103–27. doi: 10.1007/978-94-017-9050-5_6 PMID: 24962883
5. Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 1991; 66(3): 555–61. PMID: 1651173
6. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamly: the second decade. Cell 1995; 83(6): 835–9. PMID: 8521507
7. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68(2): 397–406. PMID: 1310260
8. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345(6272): 224–9. PMID: 2159111
9. Li M, Sun Y, Yuan X, Shu X, Li C. Advanced progress on the relationship between RA and its receptors and malignant tumors. Crit Rev Oncol Hematol. 2014; 91(3): 271–82. doi: 10.1016/j.critrevonc.2014.04.001 PMID: 24793339
10. Kok K, Oisinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987; 330(6148): 579–81. PMID: 2825933
11. Ferrari N, Pfahl M, Levi G. Retinoic acid receptor gamma1 (RARgamma1) levels control RARbeta2 expression in SK-N-BE2(c) neuroblastoma cells and regulate a differentiation-apoptosis switch. Mol Cell Biol. 1998; 18(11): 6482–92. PMID: 9774664

12. Li Y, Dawson MI, Agadir A, Lee MO, Jong L, Hobbs PD, et al. Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction. Int J Cancer 1998; 75(1): 88–95. PMID: 9426695

13. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, et al. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol. 1996; 16(3): 1138–49. PMID: 8622658

14. Le Maire A, Alvarez S, Shankaranarayanan P, Lera AR, Bourguet W, Gronemeyer H. Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr Top Med Chem. 2012; 12(6): 505–27. PMID: 22242853

15. Gilardi F, Desvergne B. RXRs: Collegial Partners. Subcell. Biochem. 2014; 70: 75–102. doi: 10.1007/978-94-017-9050-5_5 PMID: 24962882

16. Roberts AB, Sporn MB., editor. Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB and Goodman DS eds. The Retinoids. 2nd ed. Orlando, FL: Academic Press; 1984, Vol. 2: 209–286.

17. Bushue N, Wan YY. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010; 62(13): 1285–98. doi: 10.1016/j.addr.2010.07.003 PMID: 20654663

18. Lu T, Li W, Wu X, Wang L, Wang G, Gao D, et al. Mechanism of apoptosis of esophageal cancer EC9706 in nude mice induced by all-trans retinoic acid. Zhonghua Zhong Liu Za Zhi 2010; 32(12): 892–6. PMID: 21223795

19. Nichol JN, Garnier N, Miller WH. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemia promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. Best Pract Res Clin Haematol. 2014; 27(1): 19–31. doi: 10.1016/j.beha.2014.04.009 PMID: 24907014

20. Haubold M, Weise A, Stephan H, Dünker N. Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma cells. Int J Biol Sci. 2010; 6(7): 700–15. PMID: 21152263

21. Glozak MA, Rogers MB. Specific induction of apoptosis in P19 embryonal carcinoma cells by retinoic acid and BMP2 or BMP4. Dev Biol. 1996; 179(2): 458–70. PMID: 8903360

22. Fujita E, Soyama A, Kawabata M, Momoi T. BMP-4 and retinoic acid synergistically induce activation of caspase-9 and cause apoptosis of P19 embryonal carcinoma cells cultured as a monolayer. Cell Death Differ. 1999; 6(11): 1109–16. PMID: 10578180

23. Griege S, Hon C, Frötschl R, Hülser DF, Greger V, Hofstremke B, et al. Newly established human retinoblastoma cell lines exhibit an "immortalized" but not an invasive phenotype in vitro. Int. J Cancer 1990; 46(1):125–32. PMID: 2365495

24. Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, et al. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst 1974; 53(2):347–60. PMID: 4135597

25. McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res. 1977; 37(4): 1003–10. PMID: 844036

26. Huggenvik JI, Sharma RP. Transcriptional activation of a model reporter system by retinoids and retinoic acid receptor isoforms. Pharmacol Toxicol. 1995; 76(1): 17–22. PMID: 7753751

27. Harmon MA, Boehm MF, Heyman RA, Mangeldorf DJ. Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci U.S.A. 1995; 92(13): 6157–60. PMID: 7597096

28. Brandelbourg TD, Hu CY. Regulation of differentiating pig preadipocytes by retinoic acid. J Anim Sci. 2005; 83(1): 98–107. PMID: 15583048

29. Someren G, Sala G, Rossetti S, Ren M, Ghidoni R, Sacchi N. Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. PLOS ONE 2007; 2(9): e836. PMID: 17786207

30. Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang XK. Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem. 1999; 274(22): 15360–6. PMID: 10336422

31. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U.S.A. 2005; 102(37): 13212–7. PMID: 16141338

32. Hartmann L, Neveling K, Borkens S, Schneider H, Freund M, Grassman E, et al. Correct mRNA processing at a mutant TT splice donor in FANCC ameliorates the clinical phenotype in patients and is enhanced by delivery of suppressor U1 snRNAs. Am J Hum Genet. 2010; 87(4): 480–93. doi: 10.1016/j.ajhg.2010.08.016 PMID: 20869034
33. Yuan S, Akey CW. Apoptosome structure, assembly, and procaspase activation. Structure 2013; 21(4): 501–15. doi: 10.1016/j.str.2013.02.024 PMID: 23561633
34. Houle B, Leduc F, Bradley WE. Implication of RARβ in epidermoid (Squamous) lung cancer. Genes Chromosomes Cancer 1991; 3(5): 358–66. PMID: 1665705
35. Hu L, Crowe DL, Rheinwald JG, Chambon P, Gudas LJ. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res. 1991; 51(15): 3972–81. PMID: 1713123
36. Swisshelm K, Ryan K, Lee X, Tsou HC, Peacocke M, Sager R. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 1994; 5(2): 133–41. PMID: 8180126
37. Allegretto EA, McClurg MR, Lazarchik SB, Clemm DL, Kerner SA, Elgort MG, et al. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem. 1993; 268(35): 26625–33. PMID: 8253793
38. Nagy L, Thomázy VA, Shipley GL, Fésüs L, Lamph W, Heyman RA, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol. 1995; 15(7): 3540–51. PMID: 7791761
39. Masetti R, Biagi C, Zama D, Vendemini F, Martoni A, Morello W, et al. Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma. Adv Ther. 2012; 29(9): 747–62. doi: 10.1007/s12325-012-0047-3 PMID: 22941525
40. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76(9): 1704–9. PMID: 2224119
41. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep. 1987; 71(5): 493–515. PMID: 3552220
42. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72(2): 567–72. PMID: 3165295
43. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrisi R, Manetti L, Robertson C, et al. Chemoprevention of breast cancer: the Italian experience. J Cell Biochem Suppl. 2000; 35: 84–96. PMID: 10762020
44. Kyritsis A, Joseph G, Chader GJ. Effects of butyrate, retinol, and retinoic acid on human Y-79 retinoblastoma cells growing in monolayer cultures. J Natl Cancer Inst. 1984; 73(3): 649–54. PMID: 6590911
45. Donato LJ, Noy N. Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res. 2005; 65(18): 8193–9. PMID: 16166294
46. Pouliaki V, Mitsuakis CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, et al. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci. 2005; 46(1): 358–66. PMID: 15623796
47. Hoang TC, Bui TKL, Taguchi T, Watanabe T, Sato Y. All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein. J Exp Clin Cancer Res. 2010; 29: 165. doi: 10.1186/1756-9966-29-165 PMID: 21159206
48. Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci. 2010; 123(Pt 19): 3209–14.
49. The H de, Marchio A, Tiollais P, Dejean A. Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes. EMBO J 1989; 8(2): 429–33. PMID: 2542014
50. Lin B, Chen GQ, Xiao D, Kolluri SK, Cao X, Su H, et al. Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol. 2000; 20(3): 957–70. PMID: 10629053
51. Li A, Zhu X, Brown B, Craft CM. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2003; 44(3):996–1007. PMID: 12601020